The first selective mGlu7 agonist. Potently inhibits cAMP accumulation and stimulates GTPγS binding in recombinant cells and on membranes expressing mGlu7 (EC50 = 64 - 290 nM). Selective over other mGluR subtypes and selected ionotropic glutamate receptors up to 10 μM. Acts via a novel allosteric site and is orally active and brain penetrant. Reduces haloperidol-induced catalepsy in rats.